Endo International Names Paul Campanelli President & CEO; Affirms Guidance

(RTTNews) - Endo International plc (ENDP, ENL.TO) announced that its Board has named Paul Campanelli President and CEO, effective immediately. Campanelli currently serves as President of Endo's Generic and OTC drugs business, Par Pharmaceutical. He succeeds Rajiv De Silva, who has stepped down as President, CEO and a member of the Board.

Separately, Endo affirmed its third quarter and full year financial guidance. For the third quarter, the company expects: total revenues between $830 million and $870 million; and adjusted EPS from continuing operations between $0.77 and $0.82. For the full year 2016, the company expects: total revenues between $3.87 billion and $4.03 billion; and adjusted EPS from continuing operations between $4.50 and $4.80.